Amplifon S.p.A. stock (IT0004056880): hearing care specialist in focus after recent results

Amplifon S.p.A. has reported fresh quarterly figures and updated its outlook, keeping the global hearing care provider on the radar of investors who follow European healthcare stocks with US market exposure.

Amplifon S.p.A. has recently presented new financial figures and business updates that shed light on the momentum in its global hearing care operations, including key markets in Europe and North America. The company reported revenue growth and continued network expansion in its latest quarterly results published on 02/26/2025, according to Amplifon press release as of 02/26/2025. In parallel, the management commented on demand trends and margin development in core regions, which are relevant for investors tracking healthcare consumption and aging demographics, as summarized by Reuters as of 02/26/2025.

As of: 05/21/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Amplifon
• Sector/industry: Hearing care, medical devices, retail
• Headquarters/country: Milan, Italy
• Core markets: Europe, North America, Asia-Pacific
• Key revenue drivers: Hearing aids, audiology services, accessories
• Home exchange/listing venue: Borsa Italiana (ticker: AMP)
• Trading currency: Euro (EUR)

Amplifon S.p.A.: core business model

Amplifon S.p.A. operates one of the largest global networks of hearing care points of sale, combining own retail outlets, franchise partners, and shop-in-shop formats. The company focuses on diagnostic hearing tests, fitting of hearing aids, and after-sales support for customers, mostly seniors, but also younger people with hearing loss, as outlined in its corporate profile published on 03/18/2025 by Amplifon company profile as of 03/18/2025. This positioning places the group within the broader global healthcare and medtech universe.

The business model is built around a consultative service approach in physical locations, where audiologists and trained staff guide customers from screening through device selection and ongoing fine-tuning. Amplifon generates revenue primarily through the sale of hearing aids from leading manufacturers, complemented by its own private-label solutions and recurring service packages, according to a business description published by Borsa Italiana as of 01/15/2025. This combination of product and service revenue can support repeat visits and customer loyalty over several years.

In addition to its retail network, Amplifon invests in marketing, brand awareness, and partnerships with physicians and ENT specialists who refer patients for hearing solutions. The company emphasizes personalization of fittings and the use of digital tools, such as remote adjustments in selected markets, which can improve the overall customer experience and support efficiency. This multi-channel approach aligns with broader trends in healthcare retail, where patient convenience and perceived quality of care are increasingly important for commercial success.

Main revenue and product drivers for Amplifon S.p.A.

Revenue at Amplifon S.p.A. is driven by the volume of hearing tests and fittings performed across its global network, as well as the price and mix of hearing aids sold. In its 2024 results, the group reported consolidated revenue of approximately €2.47 billion for the year, an increase compared with 2023, supported by organic growth and acquisitions, according to Amplifon press release as of 02/26/2025. Management highlighted a solid contribution from Europe and North America, where an aging population and greater awareness of hearing health continue to support structural demand.

The product portfolio spans entry-level to premium digital hearing aids, including rechargeable devices and solutions that can connect to smartphones. Higher-end devices typically carry higher selling prices and margin potential, which can influence overall profitability when customers trade up. Amplifon also derives revenue from after-care services, including maintenance, cleanings, and software adjustments, which are often bundled with device sales and can create recurring revenue streams over the life of a device, according to the group’s 2024 annual report published on 03/19/2025 by Amplifon financial report as of 03/19/2025.

Another important driver is the company’s acquisition strategy. Amplifon regularly acquires smaller hearing care chains or individual practices to expand its footprint, particularly in fragmented markets. These deals typically add revenue and can generate synergies over time when purchasing, marketing, and back-office functions are integrated. At the same time, integration costs and execution risks must be managed carefully, a point underlined by commentary from management when discussing 2024 and early 2025 acquisitions, as summarized by Reuters as of 03/20/2025.

Seasonality and reimbursement environments can also influence revenue. In some markets, public or private insurance systems contribute to funding hearing aids, which can affect both demand timing and average selling prices. Amplifon adapts its commercial approach to each country, balancing volume growth with margin considerations. This flexibility is relevant for investors because it can help the group navigate regulatory adjustments, such as changes in coverage rules or co-payment structures, which periodically occur in European and North American healthcare systems.

Industry trends and competitive position

The global hearing care market is influenced by demographic aging, rising life expectancy, and increased awareness of the impact of untreated hearing loss on quality of life. Studies from industry observers such as the World Health Organization and sector research firms indicate that many people who could benefit from hearing aids still do not use them, suggesting long-term underpenetration. Against this backdrop, Amplifon competes with other large hearing care retailers and vertically integrated manufacturers that own both device brands and retail networks, as noted by Reuters as of 11/07/2024.

Amplifon’s competitive edge lies in its global scale and strong brand in several markets. The company emphasizes professional service quality as a key differentiator compared with more transactional channels or low-cost competitors. At the same time, new forms of distribution are emerging, including big-box retail, online providers, and over-the-counter hearing aids in the United States following regulatory changes. These developments could intensify competition but also raise overall awareness of hearing solutions, which may expand the addressable market, based on sector commentary published by Financial Times as of 10/15/2024.

Amplifon continuously invests in marketing and technology to position itself within this evolving landscape. Initiatives include modern store concepts, digital booking tools, and remote care solutions where permitted by local regulation. The company also develops its own brands and service packages to strengthen customer relationships and support differentiation. The balance between premium service positioning and competitive pricing will likely remain a central theme in the company’s strategy as consumer expectations and competitive dynamics continue to change.

Why Amplifon S.p.A. matters for US investors

Although Amplifon S.p.A. is listed in Milan, the company has a meaningful presence in North America and indirect exposure to US healthcare and consumer spending trends. The group operates hearing care locations in the United States and Canada, and it serves US residents who purchase hearing aids during travel or through cross-border channels, according to network information published on 04/10/2025 by Amplifon our presence as of 04/10/2025. For US investors, the stock offers a way to gain exposure to structural themes such as aging demographics and growth in hearing health, but through a non-US listed company.

Changes in US regulation, such as the introduction of over-the-counter hearing aids, can influence the competitive environment facing Amplifon’s North American operations. These regulatory developments may affect pricing dynamics and consumer behavior, even if the group positions itself more in the consultative, service-heavy segment of the market. As a result, macroeconomic conditions, consumer confidence, and healthcare policy in the US can have indirect effects on Amplifon’s performance, particularly in terms of volume growth and mix, as highlighted in sector coverage by Bloomberg as of 09/30/2024.

US-based institutional investors often include European healthcare firms in their portfolios as a diversification tool and as a way to access structural growth outside the domestic market. Amplifon falls into this category, combining consumer-facing characteristics with exposure to medical devices and healthcare services. Its listing on Borsa Italiana means that US investors typically access the stock through international brokerage platforms or funds that hold the shares, rather than US domestic exchanges. Currency movements between the euro and the US dollar add another layer of consideration, as returns for dollar-based investors are influenced by FX developments as well as share price performance.

Conclusion

Amplifon S.p.A. occupies a distinctive niche at the intersection of healthcare and consumer services, with a business model centered on personalized hearing care across a large international network. Recent financial results for 2024 indicate continued revenue growth and ongoing investment in expansion, while also underscoring the need to manage integration efforts and competitive challenges carefully. For US investors, the stock represents an internationally diversified way to follow long-term themes such as aging populations and hearing health, while also considering factors like regulation, currency movements, and evolving competition from new distribution channels.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.